Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

To help address this complex question, I would like to call your attention to a review of the topic by Al-Adra et al., PMID 32969590. It covers several types of malignancies, including prostate cancer (Table 4). Treating this patient will require close collaboration with the transplant surgeon, urol...

When do you add a third field for IMPORT-LOW style partial breast irradiation?

3
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I don’t usually use the 3rd field and treat with min tangent with FIF to improve homogeneity. If planning to do conformal RT then prefer an APBI dose of 30 in 5 with VMAT technique.

What is your approach for a primary tracheal squamous cell carcinoma?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Northeast Alabama Regional Medical Center

First off as you probably know this is a randomized data-free zone. So to some extent what to do here is empiric and/or based on historic outcomes, retrospective data, and so on. But here are a few quick & dirty observations...1) Surgical patients have the best survivals/outcomes. Doing tracheal sur...

What is the best IGRT strategy in treating the prostate bed (adjuvant or salvage): Daily anatomy KV images vs. fiducial seed kv images vs. CBCTs?

4
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Chicago

For our post-prostatectomy men, we use daily kV and line up to surgical clips if available (contouring out a clip each quadrant of the prostate bed if possible) with a PTV expansion of 5 mm. If clips are not present, then we use CBCT to evaluate soft tissue alignment and use a slightly larger PTV of...

What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?

8
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Beth Israel Deaconess Medical Center

Surgery of the primary did not significantly improve overall survival in which patients were randomly allocated to receive systemic therapy alone or (for responding patients) to systemic therapy followed by primary tumor resection in the trial conducted by ECOG-ACRIN (Khan et al., PMID 34995128), at...

What constraints do you use for the BID small cell lung cancer regimen?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Tennessee Oncology

The best validated constraints are from CONVERT (CALGB 30610/RTOG 0538). Cord D0.1cc < 41 GyEsophagus mean < 34 GyHeart V60 < 33%Heart V45 < 67%Heart V40 < 100%Lung V20 <40%Lung mean < 20 GyAlthough I tend to push for the LU005 constraints which I think are slightly more conservative.In addition to ...

Are there reasons to not use prostate SBRT when treating the prostate +\- proximal SV?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology

Early trials such as HYPO-RT-PC which aimed to validate a 7-fraction SBRT dose schedule by comparing it to the standard of care at the time, conventionally fractionated EBRT, utilized a treatment volume consisting of the prostate alone without the seminal vesicles (SVs). While there was some suggest...

What is the optimal duration of ADT for unfavorable intermediate risk or high risk localized prostate cancer treated with SBRT instead of conventionally fractionated or hypofractionated RT?

7
5 Answers

Mednet Member
Mednet Member
Medical Oncology · Duke University School of Medicine

There is no available data from randomized trials to support any modification in the choice of ADT (GnRH agonist vs antagonist) or use of abiraterone acetate, or on the duration of ADT (4-6 mo vs 2-3 years) based on the form of radiation, and thus I follow the NCCN guidelines that provide recommenda...

For a cutaneous malignancy near the eyelid, how do you decide whether to use an internal eye shield or an external eye shield during treatment?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

If the target is the eyelid, then use an internal eye shield.

Would you consider neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer who are cisplatin-ineligible?

3
2 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Virginia

We have level 1 evidence supporting neoadjuvant cisplatin-based chemotherapy followed by cystectomy, there is no evidence supporting non-cisplatin based chemotherapy. Patients unfit for cisplatin should proceed directly to surgery.